Stephen Yu
YOU?
Author Swipe
View article: Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade Open
Prolonged survival and durable responses in several late-stage cancers such as melanoma and lung cancer have been made possible with the use of immune checkpoint inhibitors targeting the programmed cell-death protein 1 (PD-1) or its ligand…
View article: 867 TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation
867 TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation Open
Background CD3-targeted T cell engagers are potent anti-tumor therapies, but their development often requires management of cytokine release syndrome (CRS). Subcutaneous dosing is a promising strategy to reduce CRS, but its application is …
View article: TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors
TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors Open
T cells have a unique capability to eliminate cancer cells and fight malignancies. Cancer cells have adopted multiple immune evasion mechanisms aimed at inhibiting T cells. Dramatically improved patient outcomes have been achieved with the…
View article: 632 HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors
632 HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors Open
Background Epithelial cell adhesion molecule (EpCAM) is highly expressed in many solid tumors. However, therapeutics targeting EpCAM have had limited clinical utility or failed in clinical development likely due to the expression of EpCAM …
View article: Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma Open
Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vincristine (Oncovin), and prednisone [R-CHOP]); however, prognosis is extr…
View article: Sequence analysis of ctDNA in NHL to monitor tumour progression and evolution
Sequence analysis of ctDNA in NHL to monitor tumour progression and evolution Open
NHL (non-Hodgkin lymphoma) is the fifth and sixth most prevalent cancer in Canada diagnosed annually among men and women respectively. With current conventional treatment, the five year survival rate is 67%. However, continued observations…
View article: Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits
Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits Open
Ultrasensitive methods for rare allele detection are critical to leverage the full potential offered by liquid biopsies. Here, we describe a novel molecular barcoding method for the precise detection and quantification of circulating tumor…
View article: Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma Open
Key Points Panobinostat induces responses in 28% of patients with relapsed and refractory DLBCL that are typically durable off therapy. MEF2B mutations predicted for response whereas early increase in ctDNA abundance was a strong predictor…